Medacta
Medacta International SA, headquartered in Switzerland (CH), is a leading player in the global medical device industry, specialising in orthopaedic and spinal surgery solutions. Founded in 1999, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Medacta is renowned for its innovative products, such as the M.O.R.E. (Medacta Orthopaedic Research and Education) programme, which enhances surgical techniques and patient outcomes. The company’s commitment to advanced technology and minimally invasive procedures sets it apart in the competitive landscape. With a focus on quality and precision, Medacta has achieved significant milestones, including numerous regulatory approvals and a growing portfolio of patented technologies. Its dedication to improving surgical performance and patient care solidifies its position as a trusted name in orthopaedics and spinal surgery.
DitchCarbon Score
How does Medacta's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medacta's score of 30 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medacta's reported carbon emissions
In 2024, Medacta reported total carbon emissions of approximately 1,916,000 kg CO2e, comprising 1,296,000 kg CO2e from Scope 1 and 620,000 kg CO2e from Scope 2 emissions. This marks a significant increase compared to 2023, when the company emitted about 1,458,000 kg CO2e globally, with 949,000 kg CO2e from Scope 1 and 509,000 kg CO2e from Scope 2. In 2023, Medacta's emissions in Switzerland (CH) were approximately 289,000 kg CO2e for Scope 2, with an additional 35,000 kg CO2e reported on a market-based approach. The company has not disclosed any Scope 3 emissions data. Despite the increase in emissions, Medacta has not set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further development in their sustainability strategy. Overall, Medacta's emissions data reflects the ongoing challenges faced by the industry in managing carbon footprints while striving for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 500,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | - | - | - | - | - | - | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medacta is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
